Display options
Cite
Lethongsavarn V, Pinault M, Diedhiou A, et al. Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno-geographic variations. Prostate. 2021;81(16):1365-1373doi: 10.1002/pros.24234.
Lethongsavarn, V., Pinault, M., Diedhiou, A., Guimaraes, C., Guibon, R., Bruyère, F., Mathieu, R., Rioux-Leclercq, N., Multigner, L., Brureau, L., Fournier, G., Doucet, L., Blanchet, P., Fromont, G., Zapata, A., & Thiel, J. J. (2021). Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno-geographic variations. The Prostate, 81(16), 1365-1373. https://doi.org/10.1002/pros.24234
Lethongsavarn, Vincent, et al. "Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno-geographic variations." The Prostate vol. 81,16 (2021): 1365-1373. doi: https://doi.org/10.1002/pros.24234
Lethongsavarn V, Pinault M, Diedhiou A, Guimaraes C, Guibon R, Bruyère F, Mathieu R, Rioux-Leclercq N, Multigner L, Brureau L, Fournier G, Doucet L, Blanchet P, Fromont G, Zapata A, Thiel JJ. Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno-geographic variations. Prostate. 2021 Dec;81(16):1365-1373. doi: 10.1002/pros.24234. Epub 2021 Sep 13. PMID: 34516695.
Copy Download .nbib Format: NLM
Share it on

Prostate. 2021 Dec;81(16):1365-1373. doi: 10.1002/pros.24234. Epub 2021 Sep 13.

Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno-geographic variations.

The Prostate

Vincent Lethongsavarn, Michèle Pinault, Abdoulaye Diedhiou, Cyrille Guimaraes, Roseline Guibon, Franck Bruyère, Romain Mathieu, Nathalie Rioux-Leclercq, Luc Multigner, Laurent Brureau, Georges Fournier, Laurent Doucet, P Blanchet, Gaëlle Fromont, Zapata, Thiel

Affiliations

  1. Inserm UMR1069 "Nutrition, Croissance et Cancer", Université de Tours, Tours, France.
  2. Department of Pathology, CHU de la Guadeloupe, Guadeloupe, France.
  3. Department of Urology, Université des Antilles, Pointe-à-Pitre, France.
  4. Department of Pathology, CHRU Tours, Tours, France.
  5. Department of Urology, CHRU Tours, Tours, France.
  6. Department of Urology, CHU Rennes, Rennes, France.
  7. Inserm UMR1085 - IRSET, EHESP, Université de Rennes, Rennes, France.
  8. Department of Pathology, CHU Rennes, Rennes, France.
  9. Department of Urology, CHU de la Guadeloupe, Pointe-à-Pitre, France.
  10. Department of Urology, CHU Brest, Brest, France.
  11. Department of Pathology, CHU Brest, Brest, France.

PMID: 34516695 DOI: 10.1002/pros.24234

Abstract

BACKGROUND: Prostate cancer (PCa) is more frequent and more aggressive in populations of African descent than in Caucasians. Since the fatty acid composition of peri-prostatic adipose tissue (PPAT) has been shown to differ according to the ethno-geographic origin and is involved in PCa aggressiveness, we aimed to analyze the cholesterol content of PPAT from Caucasian and African-Caribbean patients, in correlation with markers of disease aggressiveness and cholesterol metabolism in cancer tissues.

METHODS: The quantification of cholesterol in PPAT was analyzed in 52 Caucasian and 52 African-Caribbean PCa patients, with in each group 26 indolent tumors (ISUP Group1 and pT2) and 26 potentially aggressive tumors (ISUP Group 3-5 and/or pT3). The expression of proteins involved in cholesterol metabolism was analyzed by immunohistochemistry on cancer tissue samples included in tissue microarrays.

RESULTS: The amount of cholesterol esters was lower in PPAT from African-Caribbean patients compared with Caucasians, without any correlation with markers of disease aggressiveness. In cancer tissues from African-Caribbean patients, the expression of ABCA1 (involved in cholesterol efflux) was decreased, and that of SREBP-2 (involved in cholesterol uptake) was increased. In both groups of patients, SREBP-2 expression was strongly associated with that of Zeb1, a key player in the epithelial-to-mesenchymal transition (EMT) process.

CONCLUSION: These results suggest that cholesterol metabolism differs according to the ethno-geographic origin, in both PPAT and cancer tissues. In African-Caribbeans, the orientation towards accumulation of cholesterol in cancer cells is associated with a more frequent state of EMT, which may promote PCa aggressiveness in this population.

© 2021 Wiley Periodicals LLC.

Keywords: African-Caribbeans; EMT; adipose tissue; aggressiveness; cholesterol; prostate cancer

References

  1. Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating Black-White differences in prostate cancer prognosis: a systematic review and meta-analysis. Int J Cancer. 2008;123(2):430-435. - PubMed
  2. Brureau L, Multigner L, Wallois A, et al. Prostate cancer in Guadeloupe (French West Indies): incidence, mortality and clinicopathological features. Bull Cancer. 2009;96(2):165-170. - PubMed
  3. Sonn GA, Aronson W, Litwin MS. Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis. 2005;8(4):304-310. - PubMed
  4. Buschemeyer WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007;52(2):331-343. - PubMed
  5. Figiel S, Pinault M, Domingo I, et al. Fatty acid profile in peri-prostatic adipose tissue and prostate cancer aggressiveness in African-Caribbean and Caucasian patients. Eur J Cancer. 2018;91:107-115. - PubMed
  6. Lewis CA, Brault C, Peck B, et al. SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme. Oncogene. 2015;34(40):5128-5140. - PubMed
  7. Pelton K, Freeman MR, Solomon KR. Cholesterol and prostate cancer. Curr Opin Pharmacol. 2012;12(6):751-759. - PubMed
  8. Solomon KR, Freeman MR. The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am. 2011;38(3):243-259. - PubMed
  9. Platz EA, Till C, Goodman PJ, et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2807-2813. - PubMed
  10. Schnoeller TJ, Jentzmik F, Schrader AJ, Steinestel J. Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness. Oncotarget. 2017;8(29):47110-47120. - PubMed
  11. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006;98(24):1819-1825. - PubMed
  12. Lebdai S, Mathieu R, Leger J, et al. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy. Urol Oncol. 2018;36(2):80.e17-80.e24. - PubMed
  13. Tulloch-Reid MK, McFarlane-Anderson N, Bennett FI, Aiken WD, Jackson MD. Effects of cholesterol, C-reactive protein, and interleukin-6 on prostate cancer risk in a population of African ancestry. Cancer Causes Control. 2017;28(11):1313-1321. - PubMed
  14. Allott EH, Howard LE, Song H-J, et al. Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2404-2412. - PubMed
  15. Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One. 2012;7(1):e30062. - PubMed
  16. Huang B, Song B, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2(2):132-141. - PubMed
  17. Howe V, Sharpe LJ, Alexopoulos SJ, et al. Cholesterol homeostasis: How do cells sense sterol excess? Chem Phys Lipids. 2016;199:170-178. - PubMed
  18. Stopsack KH, Gerke TA, Andrén O, et al. Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis. 2017;38(8):806-811. - PubMed
  19. Schörghofer D, Kinslechner K, Preitschopf A, et al. The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence. Reprod Biol Endocrinol. 2015;13:88. - PubMed
  20. Folch J, Lees M, Sloane Stanley GH. The isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226(1):497-509. - PubMed
  21. Pinault M, Guimaraes C, Ben Hassen C, et al. Development of a novel HPTLC-based method for the simultaneous quantification of clinically relevant extracts. Lipids. 2020;55(4):403-412. - PubMed
  22. Nassar ZD, Aref AT, Miladinovic D, et al. Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer. BJU Int. 2018;121(Suppl 3):9-21. - PubMed
  23. Roman M, Wrobel TP, Panek A, Paluszkiewicz C, Kwiatek WM. Lipid droplets in prostate cancer cells and effect of irradiation studied by Raman microspectroscopy. Biochimica et Biophysica Acta (BBA) - Mol Cell Biol Lipids. 2020;1865(9):158753. - PubMed
  24. Yue S, Li J, Lee S-Y, et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 2014;19(3):393-406. - PubMed
  25. Zhu Y, Chen C-Y, Li J, Cheng J-X, Jang M, Kim K-H. In vitro exploration of ACAT contributions to lipid droplet formation during adipogenesis. J Lipid Res. 2018;59(5):820-829. - PubMed
  26. Wang Y-T, Wang Y-H, Ma Y-T, et al. ACAT-1 gene polymorphism is associated with increased susceptibility to coronary artery disease in Chinese Han population: a case-control study. Oncotarget. 2017;8(51):89055-89063. - PubMed
  27. Dereumeaux C, Saoudi A, Guldner L, et al. Chlordecone and organochlorine compound levels in the French West Indies population in 2013-2014. Environ Sci Pollut Res Int. 2020;27(33):41033-41045. - PubMed
  28. Lee J, Scheri RC, Zhang Y, Curtis LR. Chlordecone, a mixed pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) agonist, alters cholesterol homeostasis and lipoprotein metabolism in C57BL/6 mice. Toxicol Appl Pharmacol. 2008;233(2):193-202. - PubMed
  29. Kraemer FB, Khor VK, Shen W-J, Azhar S. Cholesterol ester droplets and steroidogenesis. Mol Cell Endocrinol. 2013;371(1-2):15-19. - PubMed
  30. Allott EH, Howard LE, Aronson WJ, et al. Racial differences in the association between preoperative serum cholesterol and prostate cancer recurrence: results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2016;25(3):547-554. - PubMed
  31. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2(11):862-871. - PubMed
  32. Meller S, Meyer H-A, Bethan B, et al. Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer. Oncotarget. 2016;7(2):1421-1438. - PubMed
  33. Zhou CK, Young D, Yeboah ED, et al. TMPRSS2:ERG gene fusions in prostate cancer of West African Men and a meta-analysis of racial differences. Am J Epidemiol. 2017;186(12):1352-1361. - PubMed
  34. Adamo P, Ladomery MR. The oncogene ERG: a key factor in prostate cancer. Oncogene. 2016;35(4):403-414. - PubMed
  35. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178-196. - PubMed
  36. Nakshatri H, Kumar B, Burney HN, et al. Genetic ancestry-dependent differences in breast cancer-induced field defects in the tumor-adjacent normal breast. Clin Cancer Res. 2019;25(9):2848-2859. - PubMed
  37. Figiel S, Vasseur C, Bruyere F, Rozet F, Maheo K, Fromont G. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer. Hum Pathol. 2017;61:26-32. - PubMed
  38. Saraon P, Trudel D, Kron K, et al. Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression. Prostate. 2014;74(4):372-380. - PubMed
  39. Li X, Wu JB, Li Q, Shigemura K, Chung LWK, Huang W-C. SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer. Oncotarget. 2016;7(11):12869-12884. - PubMed
  40. Demidenko R, Razanauskas D, Daniunaite K, Lazutka JR, Jankevicius F, Jarmalaite S. Frequent down-regulation of ABC transporter genes in prostate cancer. BMC Cancer. 2015;15:683. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603841/ - PubMed
  41. Xiong T, Xu G, Huang X-L, et al. ATP-binding cassette transporter A1: a promising therapy target for prostate cancer. Mol Clin Oncol. 2018;8(1):9-14. - PubMed
  42. Lee BH, Taylor MG, Robinet P, et al. Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Res. 2013;73(3):1211-1218. - PubMed
  43. Sun C, Dobi A, Mohamed A, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 2008;27(40):5348-5353. - PubMed

Publication Types